{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:07:16Z","timestamp":1792670836184,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009917","name":"NRL","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003107","name":"Federal Ministry of Health","doi-asserted-by":"publisher","award":["1369-237"],"award-info":[{"award-number":["1369-237"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004342","name":"Wyeth","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.vaccine.2020.09.050","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T03:11:21Z","timestamp":1602040281000},"page":"7542-7550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates"],"prefix":"10.1016","volume":"38","author":[{"given":"Alessia","family":"Biolchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Moschioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Tomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunella","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bambini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Claus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cecilia O.","family":"Gorla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula S.","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Lucidarme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0716-3174","authenticated-orcid":false,"given":"Muhamed-Kheir","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Comanducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Budroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia M.","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2020.09.050_b0005","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.050_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vaccine.2020.09.050_b0015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.09.050_b0020","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in S\u00e3o Paulo","volume":"340","author":"de Moraes","year":"1992","journal-title":"Brazil Lancet"},{"key":"10.1016\/j.vaccine.2020.09.050_b0025","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future","volume":"9","author":"Holst","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.09.050_b0030","first-page":"324","article-title":"Effectiveness of a mass immunization campaign against serogroup C meningococci in children in the Federal State of Santa Catarina","volume":"5","author":"Kupek","year":"2001","journal-title":"Brazil Braz J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.09.050_b0035","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/iai.62.10.4419-4424.1994","article-title":"Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy","volume":"62","author":"Milagres","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.09.050_b0040","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/21645515.2017.1412020","article-title":"Vaccine prevention of meningococcal disease in Africa: major advances, remaining challenges","volume":"14","author":"Mustapha","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2020.09.050_b0045","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1093\/cid\/civ499","article-title":"Public health impact after the introduction of PsA-TT: The first 4 years","volume":"61","author":"Diomande","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.09.050_b0050","first-page":"206","article-title":"Meningococcal disease control in countries of the African meningitis belt, 2013","volume":"89","author":"World Health Organization","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2020.09.050_b0055","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/cid\/cix993","article-title":"Current epidemiology and trends in meningococcal disease-United States, 1996\u20132015","volume":"66","author":"MacNeil","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.09.050_b0060","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1471-2334-12-202","article-title":"Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010","volume":"12","author":"Dang","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2020.09.050_b0065","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1586\/erv.13.30","article-title":"Controlling serogroup B invasive meningococcal disease: the Canadian perspective","volume":"12","author":"Bettinger","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.09.050_b0070","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"Bettinger","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.050_b0075","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1016\/j.vaccine.2015.10.055","article-title":"The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations","volume":"33","author":"Safadi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.050_b0080","doi-asserted-by":"crossref","first-page":"44102","DOI":"10.1371\/journal.pone.0044102","article-title":"Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010","volume":"7","author":"Ibarz-Pavon","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2020.09.050_b0085","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1080\/21645515.2015.1051276","article-title":"Meningococcal serogroup Y disease in Europe: continuation of high importance in some European regions in 2013","volume":"11","author":"Br\u00f6ker","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.09.050_b0090","unstructured":"European Centre for Disease Prenvention and Control. Reporting on 2010 surveillance data and 2011 epidemic intelligence data, Annual epidemiological report 2012. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/media\/en\/publications\/Publications\/Annual-Epidemiological-Report-2012.pdf [accessed 19 June 2018]."},{"key":"10.1016\/j.vaccine.2020.09.050_b0095","unstructured":"European Centre for Disease Prenvention and Control. Invasive meningococcal disease. Annual epidemiological report for 2015. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/documents\/AER_for_2015-meningococcal-disease.pdf [accessed 19 June 2018]."},{"key":"10.1016\/j.vaccine.2020.09.050_b0100","article-title":"Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies","author":"Booy","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.09.050_b0105","first-page":"24","article-title":"Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017","volume":"2019","author":"Krone","year":"2013","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2020.09.050_b0110","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1016\/j.vaccine.2016.10.022","article-title":"Meningococcal disease in the Asia-Pacific region: findings and recommendations from the Global Meningococcal Initiative","volume":"34","author":"Borrow","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.050_b0115","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1017\/S0950268811000574","article-title":"Meningococcal disease in Asia: an under-recognized public health burden","volume":"139","author":"Vyse","year":"2011","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2020.09.050_b0120","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jinf.2018.01.007","article-title":"Meningococcal disease and control in China: findings and updates from the Global Meningococcal Initiative (GMI)","volume":"76","author":"Li","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2020.09.050_b0125","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40259-015-0139-0","article-title":"Bivalent rLP2086 vaccine (Trumenba\u00ae): a review in active immunization against invasive meningococcal group B disease in individuals aged \u226510\u201325 years","volume":"29","author":"Shirley","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2020.09.050_b0130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40265-018-0869-7","article-title":"MenB-fHbp meningococcal group B vaccine (Trumenba\u00ae): a review in active immunization in individuals aged \u226510 years","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2020.09.050_b0135","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4161\/hv.23222","article-title":"Potential impact of the bivalent rLP2086 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease","volume":"9","author":"Anderson","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.09.050_b0140","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.09.050_b0145","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.09.050_b0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40265-013-0155-7","article-title":"A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program","volume":"74","author":"O'Ryan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2020.09.050_b0155","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/21645515.2015.1091131","article-title":"Vaccines for the prevention of meningococcal capsular group B disease: what have we recently learned?","volume":"12","author":"Findlow","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.09.050_b0160","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1586\/14760584.2013.814862","article-title":"A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?","volume":"12","author":"Martin","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.09.050_b0165","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/j.vaccine.2015.06.011","article-title":"Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults","volume":"33","author":"Nolan","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2020.09.050_b0170","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.050_b0175","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","article-title":"Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?","volume":"31","author":"Hong","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.050_b0180","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.vaccine.2008.12.052","article-title":"Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease","volume":"27","author":"Jacobsson","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.050_b0185","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3201\/eid2202.150369","article-title":"Effectiveness of meningococcal B vaccine against endemic hypervirulent Neisseria meningitidis W strain","volume":"22","author":"Ladhani","year":"2016","journal-title":"England Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2020.09.050_b0190","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","author":"Medini","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.050_b0195","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","article-title":"Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.050_b0200","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.09.050_b0205","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.09.050_b0210","first-page":"970","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine","volume":"12","author":"Borrow","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2020.09.050_b0215","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.vaccine.2010.02.045","article-title":"Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines","volume":"28","author":"Arguedas","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.050_b0220","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.09.050_b0225","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1074\/jbc.M110.184838","article-title":"Meningococcal group W-135 and Y capsular polysaccharides paradoxically enhance activation of the alternative pathway of complement","volume":"286","author":"Ram","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.09.050_b0230","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1080\/21645515.2019.1627159","article-title":"Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults","volume":"15","author":"Martin\u00f3n-Torres","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.09.050_b0235","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.vaccine.2016.04.009","article-title":"Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB","volume":"34","author":"Budroni","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.050_b0240","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1073\/pnas.1521142113","article-title":"Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined","volume":"113","author":"Biagini","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.09.050_b0245","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.vaccine.2018.05.081","article-title":"The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci","volume":"36","author":"Harris","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.050_b0250","first-page":"544","article-title":"Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B","volume":"71","author":"Lucidarme","year":"2015","journal-title":"C and W lineage J Infect"},{"key":"10.1016\/j.vaccine.2020.09.050_b0255","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3201\/eid2201.150432","article-title":"Surveillance of bacterial meningitis, Ethiopia, 2012\u20132013","volume":"22","author":"Mihret","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"36","key":"10.1016\/j.vaccine.2020.09.050_b0260","first-page":"1297","article-title":"Natural immunity against capsular group X N. meningitidis following an outbreak in Togo","volume":"2018","author":"Norheim","year":"2007","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20312202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20312202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:47:43Z","timestamp":1759402063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20312202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":52,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0264410X20312202"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.050","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}